Fingerprint
Dive into the research topics of 'Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis?'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis?
Lieven Pouillon, Johan Van Stappen, Peter Bossuyt, Silvio Danese, Laurent Peyrin-Biroulet
Research output: Contribution to journal › Review article › peer-review